株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アジア太平洋地域の大腸がん治療薬市場

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

発行 GlobalData 商品コード 318827
出版日 ページ情報 英文 152 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.86円で換算しております。
Back to Top
アジア太平洋地域の大腸がん治療薬市場 Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
出版日: 2018年07月01日 ページ情報: 英文 152 Pages
概要

当レポートでは、アジア太平洋地域諸国 における大腸がん (CRC) 治療薬の市場について分析し、疾患の概要や主な治療パターン、上市済み製品の概要(安全性・効能など)、現在開発中の治療薬のパイプライン情報、地域全体および主要国におけるの市場動向の見通し(今後8年間の予測値)、資本取引・事業提携の動きなどを調査しています。

第1章 目次

第2章 イントロダクション

  • 疾患の概要
  • 疫学
  • 症状
  • 病因・病態生理
    • 病因
    • 病態生理
    • 注目を集めているバイオマーカー/標的
  • 診断
    • デジタル式直腸検査
    • 便潜血検査
    • 柔軟式S状結腸鏡検査
    • 大腸内視鏡検査
    • バーチャル大腸内視鏡検査
    • 二重造影バリウム注腸
  • 病期
  • 予後
  • 治療ガイドラインとオプション
    • 外科手術・放射線治療
    • 化学療法
    • 標的療法
    • 薬物療法への抵抗
    • 治療アルゴリズム

第3章 上市済み製品

  • 概要
  • 化学療法
    • Lonsurf (トリフルリジン+チピラシル) - 大鵬薬品工業
    • TS-1 (テガフール+ギメラシル+オテラシル) - 大鵬薬品工業
    • UFT (テガフール+ウラシル) - Merck KGaA
  • 上皮成長因子受容体 (EGFR) 標的療法
    • Erbitux (セツキシマブ) - Eli Lilly/Merck KGaA
    • Vectibix (パニツムマブ) - Amgen/武田薬品工業
  • 血管新生阻害療法
    • Avastin (ベバシズマブ) - Roche
    • Cyramza (ラムシルマブ) - Eli Lilly
    • Zaltrap (ジヴ-アフリベルセプト) - Sanofi/Regeneron
  • 血管新生阻害療法
    • Stivarga (レゴラフェニブ) - Bayer/Onyx
  • 上市済み製品の効能・安全性の比較

第4章 パイプライン分析

  • 概要
  • パイプライン製品:開発段階別、分子の種類別、投薬経路別、プログラムの種類別
  • パイプライン製品:標的分子別
  • パイプライン上の有望な候補薬
    • Keytruda (ペンブロリズマブ) - Merck & Co.
    • Tecentriq plus Cotellic (アテゾリズマブ+コビメチニブ) - Roche
    • Napabucasin (BBI-608) - 大日本住友製薬
    • Encorafenib+binimetinib (LGX-818/MEK-162) - Array BioPharma
    • マシチニブ - AB Science
    • Fruquintinib (HMPL-013) - Hutchison MediPharma
    • Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
    • Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
    • Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals
  • パイプライン製品の効能・安全性の比較
  • 製品競争力分析のフレームワーク

第5章 治験分析

  • 失敗率
    • 全体的な失敗率
    • 失敗率:相別・分子の種類別
    • 失敗率:相別・標的分子別
  • 治験の規模
    • 1製品当たり参加患者数:分子の種類別、開発段階別
    • 1製品当たり参加患者数:標的分子別、開発段階別
    • 治験1件当たり参加患者数:分子の種類別、開発段階別
    • 治験1件当たり参加患者数:標的分子別、開発段階別
  • 治験期間
    • 治験期間:分子の種類別、開発段階別
    • 治験期間:標的分子別、開発段階別
  • サマリー

第6章 地域別の複数シナリオ予測

  • 概要
  • アジア太平洋地域市場
  • インド
    • 治療薬の使用パターン
    • 年間治療費
    • 市場規模
  • 中国
  • オーストラリア
  • 韓国
  • 日本

第7章 市場促進・阻害要因

第8章 資本取引および戦略的企業統合

  • ライセンス契約
  • 共同開発契約

第9章 付録

図表

1.1 List of Tables

  • Table 1: CRC Therapeutics Market, Symptoms of CRC 12
  • Table 2: CRC Therapeutics Market, Stage Definitions for CRC 18
  • Table 3: CRC Therapeutics Market, Prognosis for CRC 20
  • Table 4 CRC Therapeutics, Surgical Options for CRC 20
  • Table 5: CRC Therapeutics Market, Global, Licensing Deals Valued $10m and Above, 2007-2018 102
  • Table 6: CRC Therapeutics Market, Global, Co-development Deals Value, 2007-2018 109
  • Table 7: CRC Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 110
  • Table 8: CRC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 111
  • Table 9: CRC Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2018 119
  • Table 10: CRC Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 120
  • Table 11: CRC Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 125
  • Table 12: CRC Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 130
  • Table 13: CRC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018 131
  • Table 14: CRC Therapeutics Market, APAC, Market Forecast, 2017-2024 131
  • Table 15: CRC Therapeutics Market, India, Market Forecast, 2017-2024 131
  • Table 16: CRC Therapeutics Market, China, Market Forecast, 2017-2024 132
  • Table 17: CRC Therapeutics Market, Australia, Market Forecast, 2017-2024 132
  • Table 18: CRC Therapeutics Market, South Korea, Market Forecast, 2017-2024 133
  • Table 19: CRC Therapeutics Market, Japan, Market Forecast, 2017-2024 133

1.2 List of Figures

  • Figure 1: CRC Therapeutics Market, Australia, Age-Specific Incidence and Mortality Rate (per 100,000) in 2013 11
  • Figure 2: CRC Therapeutics, Treatment Algorithm for mCRC 25
  • Figure 3: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products, 2018 41
  • Figure 4: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for First-line Marketed Products, 2018 42
  • Figure 5: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Second-line Marketed Products, 2018 43
  • Figure 6: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Third or Fourth-line Marketed Products, 2018 43
  • Figure 7: CRC Therapeutics Market, Global, Pipeline, 2018 46
  • Figure 8: CRC Therapeutics Market, Global, Pipeline by Molecular Target, 2018 48
  • Figure 9: CRC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2018 49
  • Figure 10: CRC Therapeutics Market, APAC, Keytruda Forecast ($m), 2020-2024 51
  • Figure 11: CRC Therapeutics Market, APAC, Opdivo Forecast ($m), 2023-2024 53
  • Figure 12: CRC Therapeutics Market, APAC, Napabucasin Forecast ($m), 2022-2024 55
  • Figure 13: CRC Therapeutics Market, APAC, Encorafenib plus Binimetinib Forecast ($m), 2021-2024 57
  • Figure 14: CRC Therapeutics Market, APAC, Fruquintinib Forecast ($m), 2018-2024 58
  • Figure 15: CRC Therapeutics Market, APAC, Famitinib Forecast ($m), 2021-2024 59
  • Figure 16: CRC Therapeutics Market, APAC, Anlotinib Forecast ($m), 2020-2024 60
  • Figure 17: CRC Therapeutics Market, APAC, Donafenib Forecast ($m), 2021-2024 61
  • Figure 18: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products, 2018 61
  • Figure 19: CRC Therapeutics Market, Competitor Matrix for CRC Marketed and Pipeline Products, 2018 63
  • Figure 20: CRC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017 65
  • Figure 21: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017 66
  • Figure 22: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017 67
  • Figure 23: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017 68
  • Figure 24: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017 69
  • Figure 25: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017 70
  • Figure 26: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017 71
  • Figure 27: CRC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017 72
  • Figure 28: CRC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017 73
  • Figure 29: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 74
  • Figure 30: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 74
  • Figure 31: CRC Therapeutics Market, APAC, Treatment Patterns ('000), 2017-2024 76
  • Figure 32: CRC Therapeutics Market, APAC, Market Size ($bn), 2017-2024 76
  • Figure 33: CRC Therapeutics Market, India, Treatment Patterns ('000), 2017-2024 77
  • Figure 34: CRC Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 78
  • Figure 35: CRC Therapeutics Market, India, Market Size ($m), 2017-2024 79
  • Figure 36: CRC Therapeutics Market, China, Treatment Patterns ('000), 2017-2024 80
  • Figure 37: CRC Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 81
  • Figure 38: CRC Therapeutics Market, China, Market Size ($bn), 2017-2024 82
  • Figure 39: CRC Therapeutics Market, Australia, Treatment Patterns ('000), 2017-2024 83
  • Figure 40: CRC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 84
  • Figure 41: CRC Therapeutics Market, Australia, Market Size ($m), 2017-2024 85
  • Figure 42: CRC Therapeutics Market, South Korea, Treatment Patterns ('000), 2017-2024 86
  • Figure 43: CRC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 87
  • Figure 44: CRC Therapeutics Market, South Korea, Market Size ($m), 2017-2024 88
  • Figure 45: CRC Therapeutics Market, Japan, Treatment Patterns ('000), 2017-2024 89
  • Figure 46: CRC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 90
  • Figure 47: CRC Therapeutics Market, Japan, Market Size ($bn), 2017-2024 90
  • Figure 48: CRC Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2018 96
  • Figure 49: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 97
  • Figure 50: CRC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 98
  • Figure 51: CRC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018 99
  • Figure 52: CRC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018 100
  • Figure 53: CRC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018 103
  • Figure 54: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 104
  • Figure 55: CRC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 105
  • Figure 56: CRC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2007-2018 106
  • Figure 57: CRC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2018 107
目次
Product Code: GBIHC480MR

Abstract

  • Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
  • Summary
  • Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 50 and over - a high-risk age range for Colorectal Cancer (CRC). Over half of the incident cases of Colorectal Cancer (CRC) are diagnosed in patients over the age of 50. Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally, accounting for 0.77 million deaths in 2015.
  • The five-year prevalence population for Colorectal Cancer (CRC) in Asia-Pacific was 1.7 million in 2017. This figure has been gradually rising with the growing elderly population and increasingly Westernized lifestyles. However, growing awareness of the disease and associated risk factors together with the availability of free testing services for Colorectal Cancer (CRC) patients will increase early diagnosis and the treatment-receiving population, including targeted treatment, driving demand and contributing to market growth. Increasing affordability and healthcare access in India and China are also likely to contribute to the growth of the treatment-receiving pool significantly.
  • On the other hand, the poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The Colorectal Cancer (CRC) market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations. The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies.
  • The report "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" details the key points (etiology, epidemiology, current treatment, products currently marketed and in pipeline, market drivers and barriers) driving the Colorectal Cancer (CRC) market in the five Asia-Pacific (APAC) markets: India, China, Australia, South Korea and Japan.

Scope

  • The CRC Asia-Pacific market will be valued at $7.9 billion in 2024, growing from $5.3 billion in 2017 at a CAGR of 6%.
  • How will immune checkpoint inhibitors such as Keytruda and Opdivo contribute to growth?
  • What effect will patent expirations of currently branded therapies have on market value?
  • The CRC pipeline is large and diverse, with a strong presence of mAbs and targeted therapies.
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
  • What implications will the increased focus on targeted therapies have on the future of CRC treatment?
  • Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
  • The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, obesity and lifestyle influence the market?
  • Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $1 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 8
  • 1.2 List of Figures 8

2 Introduction 10

  • 2.1 Disease Introduction 10
  • 2.2 Epidemiology 10
  • 2.3 Symptoms 12
  • 2.4 Etiology and Pathophysiology 13
    • 2.4.1 Etiology 13
    • 2.4.2 Pathophysiology 14
    • 2.4.3 Biomarkers/Targets of Interest 14
  • 2.5 Diagnosis 16
    • 2.5.1 Digital Rectal Examination 16
    • 2.5.2 Fecal Occult Blood Test 16
    • 2.5.3 Flexible Sigmoidoscopy 16
    • 2.5.4 Colonoscopy 16
    • 2.5.5 Virtual Colonoscopy 17
    • 2.5.6 Double Contrast Barium Enema 17
  • 2.6 Disease Stages 18
  • 2.7 Prognosis 19
  • 2.8 Treatment Guidelines and Options 20
    • 2.8.1 Surgery and Radiation Therapy 20
    • 2.8.2 Chemotherapy 21
    • 2.8.3 Targeted Therapies 22
    • 2.8.4 Resistance to Pharmacological Therapies 23
    • 2.8.5 Treatment Algorithm 24

3 Marketed Products 27

  • 3.1 Overview 27
  • 3.2 Chemotherapies 27
    • 3.2.1 Lonsurf (Trifluridine plus Tipiracil) - Taiho Pharma 28
    • 3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) - Taiho Pharma 29
    • 3.2.3 UFT (tegafur plus uracil) - Merck KGaA 30
  • 3.3 Epidermal Growth Factor Receptor Targeted Therapies 31
    • 3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA 31
    • 3.3.2 Vectibix (panitumumab) - Amgen/Takeda 33
  • 3.4 Anti-angiogenesis Therapies 35
    • 3.4.1 Avastin (bevacizumab) - Roche 36
    • 3.4.2 Cyramza (ramucirumab) - Eli Lilly 38
    • 3.4.3 Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron 39
  • 3.5 Kinase Inhibitors 40
    • 3.5.1 Stivarga (regorafenib) - Bayer/Onyx 40
  • 3.6 Comparative Efficacy and Safety of Marketed Products 41

4 Pipeline Analysis 44

  • 4.1 Overview 44
  • 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 44
  • 4.3 Pipeline by Molecular Target 47
  • 4.4 Promising Pipeline Candidates 49
    • 4.4.1 Keytruda (pembrolizumab) - Merck & Co. 49
    • 4.4.2 Opdivo (nivolumab) - Bristol-Myers Squib 51
    • 4.4.3 Napabucasin (BBI-608) - Sumitomo Dainippon Pharma 53
    • 4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) - Array BioPharma 55
    • 4.4.5 Fruquintinib (HMPL-013) - Hutchison MediPharma 57
    • 4.4.6 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine 58
    • 4.4.7 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing 59
    • 4.4.8 Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals 60
  • 4.5 Comparative Efficacy and Safety of Pipeline Products 61
  • 4.6 Product Competitiveness Framework 63

5 Clinical Trial Analysis 64

  • 5.1 Failure Rate 64
    • 5.1.1 Overall Failure Rate 64
    • 5.1.2 Failure Rate by Phase and Molecule Type 66
    • 5.1.3 Failure Rate by Phase and Molecular Target 67
  • 5.2 Clinical Trial Size 68
    • 5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 68
    • 5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 69
    • 5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 69
    • 5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 71
  • 5.3 Clinical Trial Duration 71
    • 5.3.1 Trial Duration by Molecule Type and Stage of Development 72
    • 5.3.2 Trial Duration by Molecular Target and Stage of Development 73
  • 5.4 Summary of Clinical Trial Metrics 74

6 Multi-scenario Forecast 75

  • 6.1 Overview 75
  • 6.2 Asia-Pacific Market 75
  • 6.3 India 77
    • 6.3.1 Treatment Usage Patterns 77
    • 6.3.2 Annual Cost of Therapy 77
    • 6.3.3 Market Size 79
  • 6.4 China 80
    • 6.4.1 Treatment Usage Patterns 80
    • 6.4.2 Annual Cost of Therapy 81
    • 6.4.3 Market Size 82
  • 6.5 Australia 83
    • 6.5.1 Treatment Usage Patterns 83
    • 6.5.2 Annual Cost of Therapy 84
    • 6.5.3 Market Size 84
  • 6.6 South Korea 86
    • 6.6.1 Treatment Usage Patterns 86
    • 6.6.2 Annual Cost of Therapy 87
    • 6.6.3 Market Size 88
  • 6.7 Japan 89
    • 6.7.1 Treatment Usage Patterns 89
    • 6.7.2 Annual Cost of Therapy 89
    • 6.7.3 Market Size 90

7 Drivers and Barriers 92

  • 7.1 Drivers 92
    • 7.1.1 Increasing Elderly Population and Incidence of CRC 92
    • 7.1.2 Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate 92
    • 7.1.3 Increase in Mutation Testing to Drive Market Growth 92
    • 7.1.4 Availability of Novel First-, Second- and Third-Line Therapy Options in Pipeline 92
    • 7.1.5 Diversified Healthcare Reform to Boost Market Growth 93
    • 7.1.6 Diversified Health Insurance System to Help Nurture Growth 93
  • 7.2 Barriers 94
    • 7.2.1 Patent Expiration of Branded Therapies to Affect CRC Market Growth 94
    • 7.2.2 High Prices of Therapeutics to Slow Down Market Growth 94
    • 7.2.3 Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm 94
    • 7.2.4 Lack of Development of Neoadjuvant and Adjuvant Pipeline Products 94
    • 7.2.5 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India 95
    • 7.2.6 Drug Pricing Reforms 95

8 Deals and Strategic Consolidations 96

  • 8.1 Licensing Deals 96
    • 8.1.1 Deals by Region and Value 96
    • 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 97
    • 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 98
    • 8.1.4 Key Licensing Deals 100
  • 8.2 Co-development Deals 103
    • 8.2.1 Deals by Region and Value 103
    • 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 104
    • 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 105
    • 8.2.4 Key Co-development Deals 107

9 Appendix 110

  • 9.1 All Pipeline Drugs by Stage of Development 110
    • 9.1.1 Discovery 110
    • 9.1.2 Preclinical 111
    • 9.1.3 Investigational New Drug/Clinical Trial Authorization-Filed 119
    • 9.1.4 Phase I 120
    • 9.1.5 Phase II 125
    • 9.1.6 Phase III 130
    • 9.1.7 Pre-registration 131
  • 9.2 Summary of Multi-scenario Market Forecasts to 2024 131
    • 9.2.1 Asia-Pacific 131
    • 9.2.2 India 131
    • 9.2.3 China 132
    • 9.2.4 Australia 132
    • 9.2.5 South Korea 133
    • 9.2.6 Japan 133
  • 9.3 Bibliography 134
  • 9.4 Abbreviations 145
  • 9.5 Research Methodology 148
    • 9.5.1 Secondary Research 149
    • 9.5.2 Marketed Product Profiles 149
    • 9.5.3 Late-Stage Pipeline Candidates 149
    • 9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 149
    • 9.5.5 Product Competitiveness Framework 149
    • 9.5.6 Pipeline Analysis 150
    • 9.5.7 Forecasting Model 150
    • 9.5.8 Deals Data Analysis 151
  • 9.6 Contact Us 152
  • 9.7 Disclaimer 152
Back to Top